Merck is acquiring Cidara Therapeutics for $9.2 billion.

Merck is approaching a $9.2 billion deal to acquire Cidara Therapeutics. This agreement is supported by the innovative work that Cidara Therapeutics has developed on a long-acting antibody drug. The drug in question aims to provide protection against infections and is also capturing the market's attention.

The strategic merger between Merck and Cidara Therapeutics is seen as a step that is expected to have significant effects in the biopharmaceutical field. Cidara Therapeutics' innovative approach is attracting the interest of investors and the healthcare sector.